Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°áÁ÷Àå¾Ï¿¡¼­ CD44v6´Ü¹éÁú ¹ßÇö°ú ¿¹ÈÄ °ü·Ã ÀÎÀÚ¿ÍÀÇ °ü°è Expression of CD44v6 Protein in Colorectal Carcinoma

´ëÇѼÒÈ­±âÇÐȸÁö 2000³â 36±Ç 6È£ p.760 ~ 769
¼Ò¼Ó »ó¼¼Á¤º¸
¿À¼º¿í/Sung Wook Oh ±è°æö/¾ÈÈñÁ¤/±èÁ¾¿ì/ȫâ±Ç/Á¤Àº¹Ì/ÀÌÁؼº/È«¼ºÇ¥/Ȳ¼º±Ô/¹ÚÇÊ¿ø/¿Àµµ¿¬/ÀÓ±Ô¼º/Gyung Chul Kim/Hee Jung An/Jong Woo Kim/Chang Gwon Hong/Eun Mi Jung/Joon Sung Lee/Sung Pyo Hong/Sung Gyu Hwang/Pil Won Park/Do Yeon Oh/Gyu Sung Lim

Abstract

Background/Aims: CD44 is a cell surface molecule which is divided into CD44s and CD44v subsets. The relationship between th expressions of CD44 variant and progression of colorectal carcinoma has not been defined. The aims of this study were to
analyze
the expressions of CD44s and CD44v6 in colorectal adenoma and colorectal carcinoma by immunohistochemical methods and to evaluate the relationship between their expressions and various clinicopathological prognostic factors. Methods: We evaluated
retrospectively the records of 20 cases of colorectal adenoma and 56 cases of colorectal carcinoma. The expressions of CD44s and CD44v6 were investigated by immunohistochemical staining. Results: CD44s was expressed in all cases of adenoma and in
86% of
colorectal carcinoma (p>0.05). The expression rates of CD44v6 were 20% in colorectal adenoma and 80% in colorectal carcinoma (p<0.01). In colorectal carcinoma, the expression of CD44s showed no significant relationship with various prognostic
factors,
but the expression rate of CD44v6 was significantly increased according to histologic grade. There was no significant difference in the expression rate of CD44v6 according to the stage of the disease and tumor invasion. Conclusions: In colorectal
carcinoma, CD44v6 expression was significantly increased in relation with histologic grade and lymph node metastasis. These results suggested that CD44v6 could be useful as a marker of tumor progression and metastasis, but further study is
needed.

¸ñÀû : ÀúÀÚµéÀº °áÁ÷ÀåÀÇ ¼±Á¾°ú ¼±¾ÏÁ¾¿¡¼­
CD44s ¹× CD44v6 ÀÇ ¹ßÇöÀ» Á¶»çÇÏ°í, ÀÌµé ´Ü¹éÁú
ÀÇ ¹ßÇö ´Ü°è¿Í ÀüÀÌ À¯¹«¸¦ Æ÷ÇÔÇÑ ¿©·¯ ¿¹ÈÄÀÎÀÚ
¿ÍÀÇ °ü°è¸¦ ¾Ë¾Æº¸°íÀÚ º» ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù. ´ë
»ó ¹× ¹æ¹ý : 1995 ³â 6 ¿ùºÎÅÍ 1997 ³â 7 ¿ù±îÁö Æ÷õ
Áß¹®ÀÇ°ú´ëÇб³ ºÐ´çÂ÷º´¿ø¿¡¼­ °áÁ÷ÀåÀýÁ¦¼úÀ» ½Ã
Çà¹ÞÀº ȯÀÚ¿¡¼­ ¾òÀº ¼±Á¾ 20 ¿¹ ¹× ¼±¾ÏÁ¾ 56 ¿¹ÀÇ
Á¶Á÷À» ´ë»óÀ¸·Î ÇÏ¿´´Ù. °¢ Á¶Á÷¿¡¼­ CD44s ¹×
CD44v6(ÀÌÇÏ v6)´Ü¹éÁú¿¡ ´ëÇÑ ´ÜŬ·ÐÇ×ü¸¦ ÀÌ¿ë
ÇÑ avidin-biotin immunoperoxidase complex (ABC)
¹æ¹ýÀÇ ¸é¿ªÁ¶Á÷È­ÇÐÀû ¿°»öÀ» ½ÃÇàÇÏ¿´´Ù. °á°ú :
CD44s ÀÇ ¹ßÇöÀ²Àº ¼±Á¾ 100%,¼±¾ÏÁ¾ 86%·Î Â÷ÀÌ
°¡ ¾ø¾úÀ¸³ª, v6 ÀÇ ¹ßÇöÀ²Àº ¼±Á¾ 20%¼±¾ÏÁ¾ 80%
·Î ¼±¾ÏÁ¾¿¡¼­ À¯ÀÇÇÏ°Ô (p<0.01)³ô¾Æ ¼±¾ÏÁ¾À¸·ÎÀÇ
¹ßÀü ´Ü°è¿¡¼­ v6 °¡ °ü°èµÉ °ÍÀ¸·Î »ý°¢µÇ¾ú´Ù. ¼±
¾ÏÁ¾¿¡¼­ ¿©·¯ ¿¹ÈÄÀÎÀÚ¿¡ µû¸¥ CD44s ÀÇ ¹ßÇöÀº À¯
ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾úÀ¸³ª, Á¶Á÷ÇÐÀû ºÐÈ­µµ¿¡ µû¸¥ v6
ÀÇ ¹ßÇöÀ²Àº °íºÐÈ­±º 13 ¿¹ (68%),ÁߺÐÈ­±º 26 ¿¹
(87%),ÀúºÐÈ­±º 6 ¿¹ (100%)·Î ºÐÈ­µµ°¡ ³·¾ÆÁú¼ö·Ï
¹ßÇöÀÌ Áõ°¡µÇ´Â °ÍÀ» ¾Ë ¼ö ÀÖ¾ú°í (p<0.05),¸²ÇÁÀý
ÀüÀÌ À¯¹«¿¡ µû¸¥ v6 ÀÇ ¹ßÇöÀ²Àº ÀüÀÌ°¡ ¾ø´Â ±º¿¡
¼­ 17 ¿¹ (68%),ÀüÀÌ°¡ ÀÖ´Â ±º¿¡¼­´Â 20 ¿¹ (90%)·Î
ÀüÀÌ°¡ ÀϾ¼ö·Ï ¹ßÇöÀÌ Áõ°¡ÇÏ´Â °æÇâÀ» º¸¿´´Ù
(p=0.059).¾ÏÀÇ Ä§À±µµ¿Í º´±â¿¡ µû¸¥ v6 ÀÇ ¹ßÇö¿¡
À¯ÀÇÇÑ Â÷ÀÌ´Â ¾ø¾ú´Ù. °á·Ð : CD44s ´Â °áÁ÷Àå¾Ï ¹ß
»ý ÃʱâÀÎ ¼±Á¾ ´Ü°è¿¡ v6 ´Â ±×º¸´Ù ÈıâÀÎ ¼±¾ÏÁ¾
¹ß»ý ´Ü°è¿¡ °ü¿©ÇÒ °ÍÀ¸·Î »ý°¢µÈ´Ù. ƯÈ÷ °áÁ÷Àå
¾Ï¿¡¼­ v6 ´Ü¹éÀÇ ¹ßÇöÀº Á¶Á÷ÇÐÀû ºÐÈ­µµ°¡ ³·À»¼ö
·Ï ÀÇÀÇ ÀÖ°Ô Áõ°¡µÇ¸ç, ¸²ÇÁÀý ÀüÀÌ°¡ ÀÖÀ» ¶§´Â
¹ßÇöÀÌ Áõ°¡µÇ´Â °æÇâÀ» ¾Ë ¼ö ÀÖ¾ú´Ù. ±×·¯³ª ¾ÏÁ¾
ÀÇ Àü¹ÝÀûÀÎ ÁøÇà°ú ¿¹ÈÄ¿Í °ü°èµÈ ÀÓ»óÀû À¯¿ë¼º
À» ³íÇϱâ À§Çؼ­´Â ƯÀ̵µ ¸é¿¡¼­ ´õ ¿¬±¸µÇ¾î¾ß
ÇÒ °ÍÀÌ´Ù.

Å°¿öµå

°áÁ÷Àå ¼±Á¾; ¼±¾ÏÁ¾; CD44s; CD44v6; ¸é¿ªÁ¶Á÷È­ÇÐÀû ¿°»ö; Colorectal adenocarcinoma; CD44s; CD44v6; Immunohistochemical stain;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

MEDLINE
KCI
KoreaMed
KAMS